Will Small Biotech Stock Cytokinetics Undermine A Bristol Myers Buyout?

Cytokinetics (CYTK) said Monday its experimental treatment improved blood flow for patients with a genetic heart disease, and the biotech stock sprinted to a decade-high.


On today’s stock market, Cytokinetics shares rocketed 40.4% to 27 in heavy volume. The biotech stock touched its highest point since October 2009.

The biotech company studied its drug, called CK-274, in patients with hypertrophic cardiomyopathy, or HCM. With this disease, the heart muscle becomes abnormally thick, making it hard to pump blood. After 10 weeks, 92.9% of patients who received the high dose achieved significant improvements in blood flow. In the low-dose group, 78.6% of patients achieved the same result.

Now, Cytokinetics said it’s moving into a Phase 3 study.

Biotech Stock Soars To Decade-High

Biotech stock analysts were quick to compare the Cytokinetics results to MyoKardia’s. Bristol Myers Squibb (BMY) bought MyoKardia for $13.1 billion last year. MyoKardia has a rival drug called mavacamten.

A high dose of Cytokinetics’ drug hit its target in nearly 93% of patients. By comparison, MyoKardia’s treatment reached that mark in 74% of patients, Mizuho Securities analyst Salim Syed said in a note to clients. Further, CK-274 was quicker to action, reaching its maximum benefit by six weeks vs. less than 18 weeks for mavacamten.

“Bottom line, the data are clean, both on (effectiveness) and safety, and CK-274 may actually be better than MyoKardia’s mavacamten,” Syed said.

Syed has a buy rating and 36 price target on biotech stock Cytokinetics.

Cytokinetics Tops Moving Averages

The CK-274 news pushed biotech stock Cytokinetics above its 50-day and 200-day moving averages, according to

That helped reverse a general downtrend that began in late April and put the biotech stock narrowly in the red for the year.

Meanwhile, Bristol Myers stock fell 1.4% to 66.36.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Top-Rated Biotech Stock BioNTech Tacks On New Cancer Business With Kite Platform Buy

FibroGen Stock Collapses After FDA Panel Rejects Anemia Treatment

Options Trading: How To Start Using Options, How To Manage Risk

Want More IBD Insights? Subscribe To Our Investing Podcast!

See IBD Stock Lists & Get Pass/Fail Ratings For All Your Stocks With IBD Digital

Most Related Links :
todayprimenews Governmental News Finance News

Source link

Back to top button